See safety info including boxed warning. The fda has approved austedo xr in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with huntington’s disease, according to the manufacturer Austedo's drug class is a vmat2 inhibitor (vesicular monoamine transporter 2 inhibitor)
What is tardive dyskinesia (td) and chorea associated with huntington’s disease 3 it is not currently approved for pediatric patients The most common adverse reactions for austedo (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.
Austedo standard and xr tablets are currently indicated for adults for the treatment of chorea in huntington disease and tardive dyskinesia Austedo is the first vmat2 inhibitor approved by the us food and drug administration for adults with tardive dyskinesia
